Table 2.
Virologic outcomes by archived resistance category through week 144 using last on-treatment HIV-1 RNA in the proviral resistance analysis population (PRAP a).
| Baseline Resistance Class, % (n/N) | Percentage of Participants with Last Available On-Treatment HIV-1 RNA <50 copies/mL |
|
|---|---|---|
| DTG/3TC (N = 320) |
TAF-Based Regimen (N = 318) |
|
| Overall participants | >99 (319/320) | 99 (314/318) |
| Any major RAMs | 100 (81/81) | 99 (87/88) |
| No major RAMs | >99 (238/239) | 99 (227/230) |
| Any major NRTI RAMs | 100 (25/25) | 100 (17/17) |
| No major NRTI RAMs | >99 (294/295) | 99 (297/301) |
| Any major INSTI RAMs | 100 (3/3) | 100 (8/8) |
| No major INSTI RAMs | >99 (316/317) | 99 (306/310) |
| Any pre-specified INSTI substitutions | 100 (82/82) | 99 (83/84) |
| No pre-specified INSTI substitutions | >99 (237/238) | 99 (231/234) |
| Any major NNRTI RAMs | 100 (38/38) | 98 (51/52) |
| No major NNRTI RAMs | >99 (281/282) | 99 (263/266) |
| Any major PI RAMs | 100 (23/23) | 100 (19/19) |
| No major PI RAMs | >99 (296/297) | 99 (295/299) |
DTG, dolutegravir; INSTI, integrase strand transfer inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; PRAP, proviral resistance analysis population; RAM, resistance-associated mutation; TAF tenofovir alafenamide; 3TC, lamivudine. a PRAP is described in the methods.